Physician profile
Robert K Mccowan
NPI 1053380402
$3,524.77
in general payments reported to CMS, 2019-2025
33 companies · $517 in 2025
The $517 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $603 · 2020: $423 · 2021: $682 · 2022: $560 · 2023: $302 · 2024: $438 · 2025: $517.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,256.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $689.87 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Abbvie INC. | $487.41 | 2019-2025 | |
| Lilly USA, LLC | $357.78 | 2020-2024 | Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $272.83 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $211.68 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $146.52 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $121.02 | 2019-2025 | Airsupra, Farxiga |
| Amgen INC. | $117.55 | 2019-2025 | Repatha, Otezla, Repatha |
| Otsuka America Pharmaceutical, INC. | $114.57 | 2023-2025 | Rexulti, Nuedexta |
| Amarin Pharma, INC. | $105.78 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $87.39 | 2019-2021 | |
| Astellas Pharma US INC | $79.86 | 2021-2024 | Veozah |
| Esperion Therapeutics, INC. | $77.55 | 2020-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $63.87 | 2019-2024 | Xifaxan |
| Nestle Healthcare Nutrition INC. | $63.49 | 2020-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $58.70 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $41.80 | 2022 | |
| Exact Sciences Corporation | $40.10 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $37.29 | 2019-2023 | Trintellix |
| Abbott Laboratories | $37.10 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $34.60 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $33.62 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.04 | 2021-2023 | |
| Idorsia Pharmaceuticals US INC | $29.60 | 2022-2023 | Quviviq |
| Mylan Specialty L.P. | $29.46 | 2024 | Yupelri |
| Genentech USA, INC. | $27.00 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.04 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.69 | 2019 | |
| Dexcom, INC. | $19.87 | 2024 | Dexcom G6 Transmitter |
| Phathom Pharmaceuticals, INC. | $19.38 | 2025 | Voquezna |
| Biohaven Pharmaceuticals, INC. | $13.72 | 2021 | |
| Eisai INC. | $13.29 | 2021 | |
| Tris Pharma INC | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Mccowan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.